Russell M Medford

6399376, Jun 4, 2002

Nov 5, 1993

08/147878

Russell M. Medford - Atlanta GA
Clarence Frank Bennett - Carlsbad CA

ISIS Pharmaceuticals, Inc. - Carlsbad CA

C07H 2104

435375, 435 6, 435325, 435455, 536 231, 536 241, 536 243, 536 245

Genes coding for vascular cell adhesion molecules, particularly VCAM-1, are modulated through interaction of oligonucleotides with transcriptional regulatory factors which bind to the genes. Specific and effective oligonucleotides are provided which interact with the transcriptional regulatory factors to diminish their interaction with the genes and downregulate their function. Multi-modal oligonucleotides are also provided which interact both with a transcriptional regulatory factor and with another aspect of gene function.

6713621, Mar 30, 2004

Mar 9, 1995

08/401192

Russell M. Medford - Atlanta GA
Clarence Frank Bennett - Carlsbad CA

ISIS Pharmaceuticals, Inc. - Carlsbad CA
Emory University - Atlanta GA

C07H 2102

536 245, 536 231, 514 44

Genes coding for vascular cell adhesion molecules, particularly VCAM-1, are modulated through interaction of oligonucleotides with transcriptional regulatory factors which bind to the genes. Specific and effective oligonucleotides are provided which interact with the transcriptional regulatory factors to diminish their interaction with the genes and downregulate their function. Multi-modal oligonucleotides are also provided which interact both with a transcriptional regulatory factor and with another aspect of gene function.

6747061, Jun 8, 2004

Mar 21, 2001

09/815244

Russell M. Medford - Atlanta GA
Uday Saxena - Atlanta GA
Lee K. Hoong - Suwanee GA
Patricia K. Somers - Fort Collins CO

AtheroGenics, Inc. - Alpharetta GA

A61K 3134

514471, 549496

N-substituted dithiocarbamate esters, pharmaceutical compositions containing them, and methods of treating hyperproliferative disorders such as cancer by administering the N-substituted dithiocarbamate esters.

6887712, May 3, 2005

Nov 9, 1999

09/436892

Russell M. Medford - Atlanta GA, US
Uday Saxena - Atlanta GA, US

AtheroGenics, Inc. - Alpharetta GA

G01N033/92

436 71, 435 71, 435 772, 435 792, 435 794, 436501, 436515, 436523, 436536, 436537, 436546, 436518, 436524, 436528, 436 55, 436164, 436172, 436805, 436815

A method is disclosed for determining whether a compound binds to a lipoprotein such as LDL or VLDL in a manner which will lower plasma cholesterol. The method provided includes assessing the ability of the compound to form a complex with the lipoprotein, and then determining whether the newly formed complex causes a change in the structure of apoB-100 that results in increased binding affinity to an LDL receptor.

7071158, Jul 4, 2006

Feb 7, 2001

09/779086

Rebecca Chinery - Nashville TN, US
R. Daniel Beauchamp - Nashville TN, US
Robert J. Coffey - Woodside CA, US
Russell M. Medford - Atlanta GA, US
Brian E. Wadzinski - Nashville TN, US

Atherogenics, Inc. - Norcross GA

A61K 31/00
A61K 31/50

514 1, 514 34, 514183, 514185, 514284, 514492

A method to enhance the cytotoxic activity of an antineoplastic drug comprising administering an effective amount of the antineoplastic drug to a host exhibiting abnormal cell proliferation in combination with an effective cytotoxicity-increasing amount of an antioxidant. The invention also includes a method to decrease the toxicity to an antineoplastic agent or increase the therapeutic index of an antineoplastic agent administered for the treatment of a solid growth of abnormally proliferating cells, comprising administering an antioxidant prior to, with, or following the antineoplastic treatment.

20020052000, May 2, 2002

Feb 7, 2001

09/779099

Sampath Parthasarathy - Dunwoody GA, US
Russell Medford - Atlanta GA, US
R. Alexander - Atlanta GA, US

G01N033/53

435/007100

A method and kit for the diagnosis and quantification of the state of oxidation, and more specifically, the level of lipid peroxidation, of a host is provided that includes contacting a host biological sample with an antibody to an antigen formed by the reaction of a lipid hydroperoxide with a primary amine. This method assesses the risk of, or existence of, oxidative damage in the host. The invention also includes monoclonal and polyclonal antibodies, as well as antibody fragments, optionally in purified or isolated form, which are useful in this method and kit.

20050196819, Sep 8, 2005

May 3, 2005

11/121157

Russell Medford - Atlanta GA, US
Uday Saxena - Atlanta GA, US

G01N033/53
G01N033/537
G01N033/543
C12Q001/60

435007930, 435011000

A method is disclosed for determining whether a compound binds to a lipoprotein such as LDL or VLDL in a manner which will lower plasma cholesterol is provided that includes assessing the ability of the compound to form a complex with the lipoprotein, e.g., LDL or VLDL, and then determining whether the newly formed complex causes a change in the structure of apoB-100 that results in increased binding affinity to the LDL receptor. Also disclosed is a method for lowering cholesterol in a host in need thereof, including a human, is provided that includes the administration of an effective amount of a compound which binds to cholesterol-carrying lipoprotein (e.g. LDL or VLDL) in a manner that alters the three dimensional configuration of the lipoprotein and increases the binding affinity of the apoB-100 protein to the LDL receptor, including those on the surface of a hepatic cell.

20080214660, Sep 4, 2008

May 15, 2008

12/121464

Russell M. Medford - Atlanta GA, US
Patricia K. Somers - Atlanta GA, US
Lee K. Hoong - Duluth GA, US
Charles O. Meng - Alpharetta GA, US

A61K 31/341
C07C 61/16
A61K 31/192
C07C 69/00
A61P 19/02
A61P 29/00
A61K 31/216
C07D 307/02

514461, 562426, 514568, 549484, 560 9, 514532

This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.